Riamilovir
| CAS号 | 123606-06-4 | 货号 | BCP41717 |
| 中文名 | Riamilovir | ||
| 英文名 | Riamilovir | ||
| 中文别名 | |||
| 英文别名 | Triazavirin; TZV; | ||
| 分子式 | C5H4N6O3S | 分子量 | 228.19 |
| 生物活性 | Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2. | ||
| 信号通路 | Microbiology/Virology | ||
| 靶 点 | Influenza Virus | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！